Statement 29 January 2021

IFPMA Statement on EU COVID-19 Vaccines Supply


Global supply chains are key to delivering vaccines to protect citizens against COVID-19. The making of a vaccine requires many dozens of ingredients and manufacturing components which come from around the world.

It is vital that any measures proposed by the European Commission and the Member States do not restrict, hold back, or have other negative impacts on exports of vaccines or the import of key vaccine manufacturing supplies. Risking retaliatory measures from other regions at this crucial moment in the fight against COVID-19 is not in anyone’s best interest.

We are deeply concerned by European discussions that could be disruptive of our global efforts to manufacture and deliver billions of vaccines in record time. This is a time for cool heads and finding solutions. Threatening export restrictions is short sighted; and could risk undermining the supply of vaccines in Europe and around the world.

EFPIA statement here.


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit

Learn more

Media Contact

Elliot Dunster